Neil Sheppard

Company: University of Pennsylvania Center for Cellular Immunotherapies

Job title: Director & Head T Cell Engineering Lab

Seminars:

Rationale Design of Phase 1 Trial Combining Oncolytic Virotherapy with CAR-T Cells 2:30 pm

CAR-T therapy of solid tumors is limited by tumor microenvironments that exclude and suppress T cells such as huCART-meso cells targeting mesothelin VCN-01, a PH20 hyaluronidase-armed Oncolytic Virus degrades tumor extracellular matrix, reprograms the tumor microenvironment, and draws T cells into tumor lesions We designed a combination trial NCT05057715 to establish the safety, feasibility, and…Read more

day: Day Two